Results 161 to 170 of about 17,784 (227)

Clinical impact and healthcare resource utilisation in patients with unexplained or refractory chronic cough: a French national population study. [PDF]

ERJ Open Res
Guilleminault L, Le Moine G, Ruiz F, Ziad A, Goldberg M, Zins M, Roche N.   +6 more
europepmc   +1 more source

Nonpharmacological cough control therapy for chronic refractory cough and cough associated with underlying lung disease

ERJ Open Research, 2020
Sana Mohammed, John Steer, Jenny Ellis, Sean M. Parker   +3 more
doaj   +1 more source

Sodium channel blockers as add-on treatment for unexplained refractory chronic cough: a case report and review. [PDF]

Front Med (Lausanne)
Butnariu I, Balan MF, Zaharia DC, Bobocea R, Mitrică IA, Moraru A, Dionisie V, Lăptoiu VI, Antonescu-Ghelmez D, Antonescu F.   +9 more
europepmc   +1 more source

Evaluation and Management Outcomes and Burdens in Patients with Refractory Chronic Cough Referred for Behavioral Cough Suppression Therapy. [PDF]

Lung, 2021
Slovarp LJ, Jetté ME, Gillespie AI, Reynolds JE, Barkmeier-Kraemer JM.   +4 more
europepmc   +1 more source

Chronic cough: new concepts and therapeutic possibilities

, 2016
Cough is the most common symptom of the upper and lower airway diseases. In its nature, cough is a defence re-flex mechanism of the respiratory tract that is used to clear the upper and lower airways. Chronic cough, defined as cough lasting for more than
Arcimowicz, Magdalenia, Niemczyk, Kazimierz   +1 more
core  

Patient characteristics and triggers eliciting refractory chronic cough

World Allergy Organization Journal, 2020
David Muccino, George Philip, S.S. Birring, A.H. Morice, M.R. Sher, L.P. Mcgarvey, M.M. Kitt, A.M. Tershakovec, Z.J. Xu, J.A. Smith   +9 more
doaj   +1 more source

A retrospective study to understand the journey and health status of patients with unexplained or refractory chronic cough in the Netherlands. [PDF]

Chron Respir Dis
van den Berg JWK, Edens M, Oedit Doebé AR, van der Velden H, Heezen MR.   +4 more
europepmc   +1 more source

Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. [PDF]

Eur Respir J, 2021
Morice A, Smith JA, McGarvey L, Birring SS, Parker SM, Turner A, Hummel T, Gashaw I, Fels L, Klein S, Francke K, Friedrich C.   +11 more
europepmc   +1 more source

Mepolizumab for the treatment of refractory chronic cough in patients with eosinophilic airways disease (MUCOSA): a randomised, double-blind, parallel-group, placebo-controlled trial. [PDF]

Eur Respir J
Diab N, Brister D, Kum E, Wahab M, Hassan W, Beaudin S, Obminski C, Wattie J, Wiltshire L, Howie K, Killian K, Holt K, Sehmi R, Gauvreau GM, Smith JA, O'Byrne PM, Satia I.   +16 more
europepmc   +1 more source

Reply to Rui and Chen: Initial Success: Camlipixant in Refractory Chronic Cough. [PDF]

Am J Respir Crit Care Med
Smith JA.
europepmc   +1 more source